secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0001193125-24-004805
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Biosciences prelim FY2023 revenue near high end of $188M-$192M guidance
-----------------------------------------------------------------------------

- Preliminary full-year 2023 revenue expected near high end of prior guidance range of $188M-$192M.
- Final Q4 and FY2023 results and 2024 guidance to be reported on expected earnings call in late February 2024.
- CEO Wenbin Jiang to present at 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312524004805/0001193125-24-004805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312524004805/d690054d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-004805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer